Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy

Low-Dose (10-Gy) Total Skin Electron Beam Therapy for Cutaneous T-Cell Lymphoma: An Open Clinical Study and Pooled Data Analysis

“…Our study population also included 2 patients with SS, both of whom had a partial cutaneous response. The tumor burden in the peripheral blood was not checked after treatment, but given the recent reports of improvement in circulating tumor cells after standard dose TSEBT, it would be interesting to examine whether a low-dose regimen also has a beneficial systemic effect (7,8).…”

“…The opportunity for retreatments is compromised by the risk of acute and chronic skin toxicity, and retreatments are therefore limited to 2 to 3 courses in a lifetime (5,6). Because TSEBT is a skin-directed therapy, no significant systemic effect was expected; however, 2 recent interesting publications have reported an improvement in the amount of malignant T cells in the peripheral blood upon TSEBT (7,8).…”

Total Skin Electron Beam Therapy as Part of Multimodal Treatment Strategies for Primary Cutaneous T-Cell Lymphoma

“…However, cutaneous and peripheral blood improvement has been reported in 82 and 55% of patient groups, respectively. These findings indicate that antitumor immunity can be restored in addition to reducing tumor burden to minimal levels before AHSCT [46].…”

“…TSEBT as part of a therapeutic regimen seems to be effective in erythrodermic MF and SS; however, few patients sustain long-term cutaneous remission [9,29,38,49,52,61,62]. TSEBT also has a beneficial systemic effect in terms of reducing tumor burden in the peripheral blood in SS patients [46]. A combination of TSEBT and ECP (for 6 months) resulted in a CRR of 74% in patients with erythrodermic MF, with a significant improvement in DFS and cause-specific survival [61].…”

Fotoféresis en el tratamiento de Síndrome de Sézary: Caso clínico

“…Los agentes del grupo A pueden también utilizarse combinados entre ellos, como el uso de FEC asociado a agentes moduladores de respuestas biológicos (interferón, retinoides) 12,13 .…”